101 related articles for article (PubMed ID: 6121747)
1. Plasma somatostatin in normal subjects and in various diseases: increased levels in somatostatin-producing tumors.
Saito H; Saito S
Horm Metab Res; 1982 Feb; 14(2):71-6. PubMed ID: 6121747
[TBL] [Abstract][Full Text] [Related]
2. Plasma and tumor levels of somatostatin (SRIF) and somatostatin immunochemistry in medullary thyroid carcinoma: apparently discrepant preliminary results.
Franc B; Chayvialle JA; Modigliani E; Calmettes C; Caillou B; Dutrieux-Berger N; Houdent C; Kujas M
Henry Ford Hosp Med J; 1987; 35(2-3):147-8. PubMed ID: 2891647
[No Abstract] [Full Text] [Related]
3. Pentagastrin and glucagon stimulate serum somatostatin-like immunoreactivity in man.
Epstein S; Berelowitz M; Bell NH
J Clin Endocrinol Metab; 1980 Dec; 51(6):1227-31. PubMed ID: 6108330
[TBL] [Abstract][Full Text] [Related]
4. Production of immunoreactive corticotropin-releasing hormone in various neuroendocrine tumors.
Tsuchihashi T; Yamaguchi K; Abe K; Yanaihara N; Saito S
Jpn J Clin Oncol; 1992 Aug; 22(4):232-7. PubMed ID: 1359172
[TBL] [Abstract][Full Text] [Related]
5. Secretory protein 7B2. A novel tumor marker of medullary carcinoma of the thyroid.
Ohashi M; Natori S; Fujio N; Iguchi H; Nawata H
Horm Metab Res; 1990 Feb; 22(2):114-6. PubMed ID: 2323727
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects--a two-compartment open model.
Ho LT; Chen RL; Chou TY; Fong JC; Wang PS; Chou CK
Clin Physiol Biochem; 1986; 4(4):257-67. PubMed ID: 2875821
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma.
Grauer A; Schroth J; Ziegler R; Raue F
Thyroid; 1995 Aug; 5(4):287-91. PubMed ID: 7488870
[TBL] [Abstract][Full Text] [Related]
8. Plasma norepinephrine response to standing in patients with pheochromocytoma or medullary carcinoma of the thyroid.
Feldman JM; Blalock JA; Farrell RE; Wells SA
Arch Intern Med; 1979 Jan; 139(1):81-5. PubMed ID: 760688
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of somatostatin-immunoreactivity in an adrenal pheochromocytoma and a thyroid medullary carcinoma (Sipple syndrome).
Bethge N; Ahuja S; Diel F; Usadel KH
Exp Clin Endocrinol; 1988 May; 91(2):217-22. PubMed ID: 2900771
[TBL] [Abstract][Full Text] [Related]
10. Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma.
Libroia A; Verga U; Di Sacco G; Piolini M; Muratori F
Henry Ford Hosp Med J; 1989; 37(3-4):151-3. PubMed ID: 2576951
[TBL] [Abstract][Full Text] [Related]
11. Serum calcitonin in thyroid disorders and in pheochromocytoma kindred.
Hornicek FJ; Danowski TS; Robinson SM; Sweeney KT; Malinin GI
Ann Clin Lab Sci; 1986; 16(2):103-7. PubMed ID: 3963731
[TBL] [Abstract][Full Text] [Related]
12. Effect of guar intake on plasma somatostatin-like immunoreactivity in diabetic patients.
Shimoyama R; Uehara S; Itagaki Y; Izumiyama S; Hirayama A
Hokkaido Igaku Zasshi; 1982 Nov; 57(6):727-33. PubMed ID: 6134660
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.
Reubi JC; Chayvialle JA; Franc B; Cohen R; Calmettes C; Modigliani E
Lab Invest; 1991 Apr; 64(4):567-73. PubMed ID: 1673164
[TBL] [Abstract][Full Text] [Related]
14. The pancreatic glucagon and C-peptide secretion during hyperinsulinemia in euglycemic glucose clamp with or without somatostatin infusion in normal man.
Wu MS; Ho LT
Horm Metab Res; 1987 Jun; 19(6):253-6. PubMed ID: 2887501
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide as a tumor marker for medullary thyroid carcinoma.
Takami H; Ito K
Int Surg; 1992; 77(3):181-5. PubMed ID: 1399365
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin in medullary thyroid cancer. In vitro and in vivo studies.
Pacini F; Elisei R; Anelli S; Basolo F; Cola A; Pinchera A
Cancer; 1989 Mar; 63(6):1189-95. PubMed ID: 2563668
[TBL] [Abstract][Full Text] [Related]
18. Molecular heterogeneity and biological activity of immunoreactive somatostatin in medullary carcinoma of the thyroid.
Saito S; Saito H; Matsumura M; Ishimaru K; Sano T
J Clin Endocrinol Metab; 1981 Dec; 53(6):1117-22. PubMed ID: 6117566
[TBL] [Abstract][Full Text] [Related]
19. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.
Machens A; Hoffmann F; Sekulla C; Dralle H
Endocr Relat Cancer; 2009 Dec; 16(4):1291-8. PubMed ID: 19726541
[TBL] [Abstract][Full Text] [Related]
20. Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma.
Letizia C; De Toma G; Caliumi C; Cerci S; Massa R; Loria RD; Alo P; Marinoni EM; Diacinti D; D'Erasmo E
Horm Metab Res; 2001 May; 33(5):290-4. PubMed ID: 11440275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
